Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Senate Committee to Hold Vote Next Week on Nominee for FDA Commissioner

  • Post author:PacConAdmin
  • Post published:January 4, 2022
  • Post category:Drug Industry Daily

A Senate committee will vote whether to approve Robert Califf’s nomination to become FDA commissioner on Wednesday, Jan. 12 — a critical step before the full chamber can hold a…

Continue ReadingSenate Committee to Hold Vote Next Week on Nominee for FDA Commissioner

Applied Therapeutics Holds Off AT-007 Regulatory Push

  • Post author:PacConAdmin
  • Post published:January 4, 2022
  • Post category:Drug Industry Daily

Applied Therapeutics got some coal in its stocking last week, when the FDA said the company needs clinical outcomes data, not just biomarker numbers, to support a New Drug Application…

Continue ReadingApplied Therapeutics Holds Off AT-007 Regulatory Push

FDA Investigators See Shortcomings at Novartis Gene Therapies Facility

  • Post author:PacConAdmin
  • Post published:December 31, 2021
  • Post category:Drug Industry Daily

Novartis Gene Therapies’ Libertyville, Ill., plant, which produces Zolgensma — the world’s most expensive drug at more than $2.1 million per treatment — has drawn a Form 483 with five…

Continue ReadingFDA Investigators See Shortcomings at Novartis Gene Therapies Facility

Xeris Wins FDA Approval of Recorlev for Cushing’s Syndrome

  • Post author:PacConAdmin
  • Post published:December 31, 2021
  • Post category:Drug Industry Daily

The FDA has approved Xeris Biopharma’s Recorlev (levoketoconazole) for treating hypercortisolemia in adults with Cushing’s syndrome who are unable to undergo surgery. Source: Drug Industry Daily

Continue ReadingXeris Wins FDA Approval of Recorlev for Cushing’s Syndrome

Without mRNA Booster, CoronaVac Is Useless Against Omicron

  • Post author:PacConAdmin
  • Post published:December 31, 2021
  • Post category:Drug Industry Daily

CoronaVac, Sinovac’s COVID-19 vaccine, appears to be completely ineffective against the Omicron variant unless boosted with an mRNA vaccine, new data suggest. Source: Drug Industry Daily

Continue ReadingWithout mRNA Booster, CoronaVac Is Useless Against Omicron

Pandemic-Era Strategy Has Limitations for Future Drug Development, Survey Finds

  • Post author:PacConAdmin
  • Post published:December 31, 2021
  • Post category:Drug Industry Daily

The approach taken by drugmakers during the pandemic turned out COVID-19 vaccines in record time, but it has some shortcomings for use in future drug development and manufacturing, according to…

Continue ReadingPandemic-Era Strategy Has Limitations for Future Drug Development, Survey Finds

FDA Set to Authorize Pfizer COVID-19 Booster Shot in Adolescents

  • Post author:PacConAdmin
  • Post published:December 30, 2021
  • Post category:Drug Industry Daily

The FDA is poised to authorize a third booster dose of the Pfizer-BioNTech COVID-19 vaccine for use in adolescents aged 12 to 15. Source: Drug Industry Daily

Continue ReadingFDA Set to Authorize Pfizer COVID-19 Booster Shot in Adolescents

Sanofi’s Push to Reinstate Lantus Patents Blocked by Federal Court

  • Post author:PacConAdmin
  • Post published:December 30, 2021
  • Post category:Drug Industry Daily

A federal court has rejected Sanofi’s attempts to reinstate key patents covering a drug-device combination product dispensing its insulin blockbuster Lantus. Source: Drug Industry Daily

Continue ReadingSanofi’s Push to Reinstate Lantus Patents Blocked by Federal Court

Jury Finds Teva Liable in New York’s Opioid Trial

  • Post author:PacConAdmin
  • Post published:December 30, 2021
  • Post category:Drug Industry Daily

A New York jury has found Teva Pharmaceuticals guilty of fueling the state’s opioid crisis through misleading marketing about the risks of its highly addictive painkillers. Source: Drug Industry Daily

Continue ReadingJury Finds Teva Liable in New York’s Opioid Trial

BridgeBio’s Potential Cardiomyopathy Treatment Can’t Cross the Phase 3 Finish Line

  • Post author:PacConAdmin
  • Post published:December 30, 2021
  • Post category:Drug Industry Daily

BridgeBio’s investigational cardiomyopathy molecule acoramidis (AG10) fell short of the phase 3 finish line this week, when it not only failed its primary endpoint, but was associated with decreases in…

Continue ReadingBridgeBio’s Potential Cardiomyopathy Treatment Can’t Cross the Phase 3 Finish Line
  • Go to the previous page
  • 1
  • …
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.